secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001193125-25-268043
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q3 net loss narrows to $34.4M; cash $344M after $191M offering
---------------------------------------------------------------------

- Net loss $34.4M ($0.37/sh) vs $72.7M ($1.07/sh) in Q3 2024; R&D $19.9M, SG&A $16.2M.
- Cash and securities $344M at Sept 30, up from $180.8M at June 30; cash runway into 2028.
- Phase 3 LUCIDITY trial of avexitide recruitment completion expected Q1 2026; topline data Q3 2026.
- Phase 1 LUMINA trial of AMX0114 in ALS fully enrolled cohort 1; early data at Dec symposium.
- Plan to initiate Phase 3 trial of AMX0035 in Wolfram syndrome H2 2026 pending FDA alignment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/0001193125-25-268043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312525268043/amlx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-268043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer